| Autor: |
Burger AJ; Beth Israel Deaconess Medical Center, Non-invasive Cardiology Laboratory, Baker-3, 1 Deaconess Road, Boston, MA 02215, USA. aburger@caregroup.harvard.edu, Burger MR |
| Jazyk: |
angličtina |
| Zdroj: |
IDrugs : the investigational drugs journal [IDrugs] 2002 Jul; Vol. 5 (7), pp. 703-9. |
| Abstrakt: |
Nesiritide is a recombinant B-type (brain) natriuretic peptide developed by Scios for the potential treatment of congestive heart failure (CHF). In August 2001, the product was approved and launched in the US for the intravenous treatment of patients with acute decompensated congestive heart failure (ADCHF) who have dyspnea at rest or at minimal activity [418946], [420072]. By March 2002, Scios' European development partner, GlaxoSmithKline, expected to file a Marketing Authorization Application (MAA) for nesiritide in Europe in 2002 [446957]. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
